GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Shanghai Pharmaceuticals Holding Co Ltd (SHSE:601607) » Definitions » Revenue

Shanghai Pharmaceuticals Holding Co (SHSE:601607) Revenue : ¥260,295 Mil (TTM As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Shanghai Pharmaceuticals Holding Co Revenue?

Shanghai Pharmaceuticals Holding Co's revenue for the three months ended in Dec. 2023 was ¥62,787 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ¥260,295 Mil. Shanghai Pharmaceuticals Holding Co's Revenue per Share for the three months ended in Dec. 2023 was ¥16.89. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ¥70.47.

Good Sign:

Shanghai Pharmaceuticals Holding Co Ltd has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Shanghai Pharmaceuticals Holding Co was 6.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 3.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Shanghai Pharmaceuticals Holding Co's highest 3-Year average Revenue per Share Growth Rate was 141.00% per year. The lowest was -15.40% per year. And the median was 13.60% per year.


Shanghai Pharmaceuticals Holding Co Revenue Historical Data

The historical data trend for Shanghai Pharmaceuticals Holding Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Pharmaceuticals Holding Co Revenue Chart

Shanghai Pharmaceuticals Holding Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 186,565.80 191,909.16 215,824.26 231,981.30 260,295.09

Shanghai Pharmaceuticals Holding Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57,369.38 66,226.46 66,365.70 64,916.16 62,786.78

Competitive Comparison of Shanghai Pharmaceuticals Holding Co's Revenue

For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Pharmaceuticals Holding Co's Revenue Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Revenue falls into.



Shanghai Pharmaceuticals Holding Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥260,295 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Pharmaceuticals Holding Co  (SHSE:601607) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Shanghai Pharmaceuticals Holding Co Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Pharmaceuticals Holding Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Pharmaceuticals Holding Co (SHSE:601607) Business Description

Traded in Other Exchanges
Address
No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding is a vertically integrated Chinese healthcare company that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the second-largest distributor by revenue and has a strong distribution presence in Eastern China.

Shanghai Pharmaceuticals Holding Co (SHSE:601607) Headlines

No Headlines